Monsanto Company (NYSE:MON) has been assigned an average rating of “Buy” from the twenty-seven analysts that are presently covering the stock. Two investment analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $114.61.
A number of research firms recently issued reports on MON. Vetr downgraded shares of Monsanto Company from a “buy” rating to a “hold” rating and set a $118.00 target price for the company. in a research report on Tuesday, March 7th. Zacks Investment Research upgraded shares of Monsanto Company from a “hold” rating to a “buy” rating and set a $128.00 target price for the company in a research report on Tuesday, March 7th. Royal Bank of Canada began coverage on shares of Monsanto Company in a research report on Thursday, February 23rd. They set a “sector perform” rating and a $118.00 target price for the company. CLSA upgraded shares of Monsanto Company from an “underperform” rating to an “outperform” rating in a research report on Friday, January 6th. They noted that the move was a valuation call. Finally, Sanford C. Bernstein set a $105.00 target price on shares of Monsanto Company and gave the company a “neutral” rating in a research report on Thursday, January 5th.
WARNING: This news story was originally published by Web Breaking News and is owned by of Web Breaking News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at http://www.webbreakingnews.com/2017/03/25/brokerages-set-monsanto-company-mon-price-target-at-114-61.html.
In other news, EVP Steven Mizell sold 2,525 shares of the business’s stock in a transaction dated Tuesday, January 10th. The shares were sold at an average price of $108.56, for a total transaction of $274,114.00. Following the completion of the sale, the executive vice president now owns 43,711 shares of the company’s stock, valued at $4,745,266.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael K. Stern sold 5,670 shares of the business’s stock in a transaction dated Wednesday, January 25th. The stock was sold at an average price of $110.00, for a total transaction of $623,700.00. Following the sale, the chief executive officer now directly owns 20,534 shares of the company’s stock, valued at approximately $2,258,740. The disclosure for this sale can be found here. 0.79% of the stock is owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Gould Asset Management LLC CA boosted its stake in Monsanto Company by 0.5% in the fourth quarter. Gould Asset Management LLC CA now owns 2,750 shares of the company’s stock worth $289,000 after buying an additional 15 shares in the last quarter. Bradley Foster & Sargent Inc. CT boosted its stake in Monsanto Company by 0.3% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 5,838 shares of the company’s stock worth $597,000 after buying an additional 18 shares in the last quarter. Advisor Partners LLC boosted its stake in Monsanto Company by 0.4% in the third quarter. Advisor Partners LLC now owns 6,264 shares of the company’s stock worth $640,000 after buying an additional 26 shares in the last quarter. Gerstein Fisher boosted its stake in Monsanto Company by 0.8% in the third quarter. Gerstein Fisher now owns 4,434 shares of the company’s stock worth $453,000 after buying an additional 37 shares in the last quarter. Finally, Trust Co. of Vermont boosted its stake in Monsanto Company by 0.8% in the third quarter. Trust Co. of Vermont now owns 4,972 shares of the company’s stock worth $508,000 after buying an additional 40 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.
Shares of Monsanto Company (NYSE:MON) opened at 113.67 on Monday. Monsanto Company has a 52 week low of $84.79 and a 52 week high of $116.04. The stock has a market cap of $49.85 billion, a price-to-earnings ratio of 31.17 and a beta of 0.93. The firm has a 50-day moving average price of $111.83 and a 200-day moving average price of $106.00.
Monsanto Company (NYSE:MON) last posted its quarterly earnings data on Thursday, January 5th. The company reported $0.21 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.20. Monsanto Company had a net margin of 11.61% and a return on equity of 47.05%. The business earned $2.22 billion during the quarter. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. The company’s quarterly revenue was up 19.4% on a year-over-year basis. On average, equities analysts anticipate that Monsanto Company will post $4.74 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 28th. Stockholders of record on Friday, April 7th will be paid a dividend of $0.54 per share. The ex-dividend date of this dividend is Wednesday, April 5th. This represents a $2.16 dividend on an annualized basis and a dividend yield of 1.90%. Monsanto Company’s dividend payout ratio is currently 58.86%.
Monsanto Company Company Profile
Monsanto Company (Monsanto), along with its subsidiaries, is a provider of agricultural products for farmers. The Company provides seeds, biotechnology trait products, herbicides and precision agriculture tools to farmers. The Company operates through two segments: Seeds and Genomics, and Agricultural Productivity.
Receive News & Ratings for Monsanto Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monsanto Company and related companies with MarketBeat.com's FREE daily email newsletter.